Kelun-Biotech reported rising sales of its signature cancer drug

Precision cancer drugs show promise for Kelun-Biotech

The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…
RemeGen as problems and losses pile up

No respite for RemeGen as problems and losses pile up

The developer of innovative drugs has sustained a series of blows to its finances, corporate partnerships, management team and star product, leaving investors jittery Key Takeaways: Despite rising revenue, RemeGen…